US 11,918,770 B2
Implants for localized drug delivery and methods of use thereof
Pamela Munster, Hillsborough, CA (US); Jim Kiriakis, Corte Madera, CA (US); Hani Sbitany, San Francisco, CA (US); and Scott Thomas, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Feb. 7, 2022, as Appl. No. 17/666,138.
Application 17/666,138 is a continuation of application No. 16/273,760, filed on Feb. 12, 2019, granted, now 11,324,935.
Application 16/273,760 is a continuation of application No. 15/502,742, granted, now 10,912,933, issued on Feb. 9, 2021, previously published as PCT/US2015/045687, filed on Aug. 18, 2015.
Claims priority of provisional application 62/039,302, filed on Aug. 19, 2014.
Prior Publication US 2022/0184362 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 31/00 (2006.01); A61K 9/00 (2006.01); A61K 31/56 (2006.01); A61K 31/565 (2006.01); A61L 27/18 (2006.01); A61L 27/54 (2006.01)
CPC A61M 31/002 (2013.01) [A61K 9/0004 (2013.01); A61K 9/0024 (2013.01); A61K 9/0041 (2013.01); A61K 9/0092 (2013.01); A61K 31/56 (2013.01); A61K 31/565 (2013.01); A61L 27/18 (2013.01); A61L 27/54 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method of treating prostate cancer in a subject, the method comprising:
providing a depot comprising a silicone implant having at least one silicone wall loaded with a hormone-modulating active agent, wherein said at least one silicone wall is permeable to said hormone-modulating active agent and the only means for the hormone-modulating active agent to exit the silicone implant is by diffusing through the at least one silicone wall,
the depot having a first, second and third orthogonal dimension, and wherein a length (h) of the silicone implant is longer than the longest dimension of the first, second and third orthogonal dimension,
implanting the depot into or adjacent a prostate with the at least one silicone wall abutting the prostate;
the depot delivering said hormone-modulating active agent to said prostate in said subject as said hormone-modulating active agent diffuses through the at least one silicone wall when implanted in said prostate in said subject.